265 related articles for article (PubMed ID: 25297747)
1. [New mutations in myeloproliferative neoplasms; 2014 update].
Kirito K
Rinsho Ketsueki; 2014 Oct; 55(10):1833-40. PubMed ID: 25297747
[No Abstract] [Full Text] [Related]
2. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
3. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
4. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
5. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
6. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
[No Abstract] [Full Text] [Related]
7. Genetically informed therapy in leukemia.
Radich J
N Engl J Med; 2013 May; 368(19):1838-9. PubMed ID: 23656651
[No Abstract] [Full Text] [Related]
8. CALR mutation studies in chronic neutrophilic leukemia.
Lasho TL; Elliott MA; Pardanani A; Tefferi A
Am J Hematol; 2014 Apr; 89(4):450. PubMed ID: 24421250
[No Abstract] [Full Text] [Related]
9. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
10. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
11. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
12. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
[TBL] [Abstract][Full Text] [Related]
13. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Gotoh A; Komatsu N
Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
[No Abstract] [Full Text] [Related]
14. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
15. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
16. Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms.
Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Impera L; Minervini CF; Brunetti C; Ricco A; Orsini P; Cumbo C; Specchia G; Albano F
Ann Hematol; 2016 Sep; 95(9):1559-60. PubMed ID: 27365140
[No Abstract] [Full Text] [Related]
17. Calreticulin mutation burden--is it a stable clone in patients with essential thrombocythemia and myelofibrosis?
Shuly Y; Nagar M; Ben-Asaf L; Kneller A; Steinberg DM; Amariglio N; Salomon O
Blood Cells Mol Dis; 2015 Dec; 55(4):281-3. PubMed ID: 26460248
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
